NCT06719128

A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants

An Open-Label, Nonrandomized, Single-Dose, Safety and Pharmacokinetic Study of LY3537982 in Participants With Hepatic Impairment and Healthy Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 46 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to assess how olomorasib gets into the blood stream and how long it takes the body to remove it when administered to participants with mild, moderate and severe impaired liver function compared to participants with normal liver function. The safety and tolerability of olomorasib will also be evaluated. The study may last up to 6 weeks for each participant including the screening period.

Conditions

• Hepatic Insufficiency
• Healthy

Interventions

Type	Name	Description
DRUG	Olomorasib	Administered orally.

Timeline

• Start date: 2024-12-06
• Primary completion: 2025-08-25
• Completion: 2025-08-25
• First posted: 2024-12-05
• Last updated: 2025-09-22

Locations

4 sites across 1 country: United States

Regulatory

• FDA-regulated drug study